Richard Rudick
Director/Board Member at IMMUNIC, INC.
Net worth: - $ as of 29/04/2024
Network origin in Richard Rudick first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
130
| Public Company | Pharmaceuticals: Major | 130 |
| Public Company | Pharmaceuticals: Major | 13 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Richard Rudick via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Chairman Chief Executive Officer Founder Director/Board Member | |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Director of Finance/CFO Chief Executive Officer Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Director/Board Member Corporate Officer/Principal Masters Business Admin Corporate Officer/Principal Undergraduate Degree | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | President President Director/Board Member Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree Undergraduate Degree | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Corporate Officer/Principal Consultant / Advisor Consultant / Advisor Consultant / Advisor | |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Pharmaceuticals: Major | Chairman Chairman Director/Board Member Founder | |
| University of Michigan | College/University | Masters Business Admin Undergraduate Degree Masters Business Admin Graduate Degree | |
| BOSTON SCIENTIFIC CORPORATION | Medical Specialties | Director of Finance/CFO Corporate Officer/Principal Public Communications Contact | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Director/Board Member Graduate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Corporate Officer/Principal Graduate Degree | |
| UNITY BIOTECHNOLOGY, INC. | Biotechnology | Comptroller/Controller/Auditor Director of Finance/CFO Director/Board Member | |
| OVID THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member President Chief Operating Officer | |
| AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| University of Massachusetts | College/University | Doctorate Degree Graduate Degree Undergraduate Degree | |
Minovia Therapeutics Ltd.
 Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Pharmaceuticals: Major | Chairman Director/Board Member Director of Finance/CFO | |
| PEPSICO, INC. | Food: Specialty/Candy | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| VOYAGER THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Operating Officer Director of Finance/CFO | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel Corporate Officer/Principal | |
| 4SC AG | Biotechnology | Chairman Founder Corporate Officer/Principal | |
| SAREPTA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| FULCRUM THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal Human Resources Officer Comptroller/Controller/Auditor | |
| Columbia Business School | College/University | Masters Business Admin Masters Business Admin | |
| Ludwig-Maximilians-Universität München | College/University | Graduate Degree Doctorate Degree | |
| VISTERRA INC | Pharmaceuticals: Major | General Counsel Director/Board Member | |
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| VIR BIOTECHNOLOGY, INC. | Biotechnology | Director/Board Member Chief Operating Officer | |
| The California State University | College/University | Undergraduate Degree Graduate Degree | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | General Counsel Director/Board Member | |
| Immunic Research GmbH | Chief Executive Officer Chief Executive Officer | ||
| FOGHORN THERAPEUTICS INC. | Biotechnology | Chief Operating Officer Human Resources Officer | |
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Human Resources Officer Public Communications Contact | |
| NOVAVAX, INC. | Biotechnology | Director of Finance/CFO Director of Finance/CFO | |
| Fondation Santé | Director/Board Member Founder | ||
| University of Georgia | College/University | Undergraduate Degree Doctorate Degree | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
Biogen GmbH
 Biogen GmbH Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen GmbH is a pioneer in the field of neuroscience since 1978. The company is based in Ismaning, Germany. Biogen focuses on research in therapeutic areas with a strong emphasis on difficult-to-treat diseases. The German company was founded in 1978 by Charles Weissman, Kenneth Murray, Heinz Schaller, Phillip Sharp, Walter Gilbert. The CEO is Michel Pericles Vounatsos. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| SANOFI | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | President Director/Board Member |
Statistics
International
| United States | 42 |
| Germany | 6 |
| Israel | 2 |
| Ireland | 2 |
| Greece | 2 |
Sectoral
| Health Technology | 33 |
| Consumer Services | 12 |
| Finance | 3 |
| Consumer Durables | 2 |
| Consumer Non-Durables | 2 |
Operational
| Director/Board Member | 358 |
| Corporate Officer/Principal | 220 |
| Independent Dir/Board Member | 95 |
| Undergraduate Degree | 75 |
| Chief Executive Officer | 65 |
Most connected contacts
| Insiders | |
|---|---|
| William Hawkins | 49 |
| Tamar Howson | 41 |
| Jörg Neermann | 34 |
| George Scangos | 33 |
| William Young | 32 |
| Steven Holtzman | 28 |
| Douglas Williams | 25 |
| Vincent Ossipow | 22 |
| Joanne Viney | 18 |
| Robin Kramer | 17 |
| Lynne Sullivan | 16 |
| Adriana Karaboutis | 16 |
| Barclay Phillips | 16 |
| Michael Ehlers | 15 |
| Spyridon Artavanis-Tsakonas | 15 |
- Stock Market
- Insiders
- Richard Rudick
- Company connections
